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Abstract
Background: Feline coronavirus (FCoV) exists as two pathotypes, and FCoV spike gene mutations are considered
responsible for the pathotypic switch in feline infectious peritonitis (FIP) pathogenesis. The aim of this study was to
evaluate sensitivity and specificity of a real-time reverse transcriptase polymerase chain reaction (RT-PCR) specifically
designed to detect FCoV spike gene mutations at two nucleotide positions. It was hypothesized that this test
would correctly discriminate feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Methods: The study included 63 cats with signs consistent with FIP. FIP was confirmed in 38 cats. Twenty-five control
cats were definitively diagnosed with a disease other than FIP. Effusion and/or serum/plasma samples were examined
by real-time RT-PCR targeting the two FCoV spike gene fusion peptide mutations M1058 L and S1060A using an allelic
discrimination approach. Sensitivity, specificity, negative and positive predictive values including 95% confidence
intervals (95% CI) were calculated.
Results: FIPV was detected in the effusion of 25/59 cats, one of them being a control cat with chronic kidney disease.
A mixed population of FIPV/FECV was detected in the effusion of 2/59 cats; all of them had FIP. RT-PCR was negative or
the pathotype could not be determined in 34/59 effusion samples. In effusion, sensitivity was 68.6% (95% CI 50.7–83.2),
specificity was 95.8% (95% CI 78.9–99.9). No serum/plasma samples were positive for FIPV.
Conclusions: Although specificity of the test in effusions was high, one false positive result occurred. The use of
serum/plasma cannot be recommended due to a low viral load in blood.
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coronavirus (FCoV), Feline enteric coronavirus (FECV), Feline infectious peritonitis virus (FIPV)
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Background
The key event in the pathogenesis of feline infectious peri-
tonitis (FIP) is the switch in viral cell tropism, which origi-
nates from mutations of the feline coronavirus (FCoV)
genome [1]. According to the internal mutation hypoth-
esis, feline infectious peritonitis virus (FIPV) emerges
from feline enteric coronavirus (FECV) by spontaneous
mutations within an infected cat [2, 3]. While FECV
causes asymptomatic infection or mild enteritis and is
widespread among the cat population [4–6] and especially
common in multi-cat environments [7–9], FIPV causes
FIP, a lethal immune-mediated disease [10, 11]. FECV has a
tropism for the small intestine apical villi epithelium [4, 12],
while FIPV can infect monocytes/macrophages and repli-
cate sufficiently within these cells to allow systemic spread
and macrophage activation [13].
Mutations in the FCoV spike gene and resulting amino
acid substitutions in the spike protein are considered
responsible for the acquisition of macrophage tropism
due to the spike protein’s role in receptor binding and
cell entry [14–16]. Although amino acid substitutions
M1058L and S1060A within the spike protein correlated
with the FIP phenotype in >95% of cases in one study
[15], a subsequent study found them to be rather associ-
ated with systemic spread of FCoV in cats with and
without FIP [14]. Focusing on a furin cleavage site in the
region between receptor-binding and fusion domains of
the spike gene, a recent study detected functionally rele-
vant mutations strongly correlated with FIP and docu-
mented the emergence of one of these substitutions in a
cat during the development of FIP [16].
Definitive ante-mortem diagnosis currently still requires
invasive tissue sample collection for immunohistochemi-
cal demonstration of FCoV antigen in macrophages in tis-
sue lesions [17–20]. Reverse transcriptase polymerase
chain reaction (RT-PCR) is frequently applied to detect
FCoV RNA in diagnostic samples, and recent studies re-
ported relatively satisfying results for real-time RT-PCR
results using different materials [21–23]. Nevertheless,
standard RT-PCR cannot distinguish FECV from FIPV
and has been shown to detect FCoV RNA also in the
blood of healthy cats that never developed FIP [24, 25].
Therefore, it was the aim of this study to evaluate sen-
sitivity and specificity of a real-time RT-PCR (FIP Virus
RealPCR Test, IDEXX Laboratories) able to discriminate
between FECV and FIPV in effusions and serum/plasma.
It was hypothesized that this discriminative PCR would
correctly identify FIPV and thus, would be a non-
invasive and reliable method to definitively diagnose FIP.
Methods
Animals
Overall, 63 cats with signs consistent with FIP were in-
cluded in the study. All cats were presented either as
sick feline patients (n = 48) or directly submitted for
necropsy (n = 15).
For 38 cats (FIP group, Table 1), a definitive diagnosis
of FIP was established post-mortem either by histopath-
ology (n = 10) (Fig. 1a-c), or by histopathology and
immunohistochemical (IHC) staining of FCoV antigen in
tissue samples (Fig. 1d) obtained at necropsy (n = 28). In
the cats with histopathological confirmation, a diagnosis
of FIP was based on the occurrence of effusions (Fig. 1a)
and/or yellow to white foci or nodules in different
organs (Fig. 1b) plus presence of typical histological
lesions, including plasma-cellular perivasculitis and/or
accumulation of plasma cells accompanied by a necro-
purulent inflammation (Fig. 1c).
Cats in the control group (n = 25) were suspected of
having FIP (Table 2) based on the existence of one or
more of the following signs consistent with FIP: effusion
(n = 24), fever with ≤20,000 white blood cells/μL and
≤1000 band neutrophils/μL (n = 1), icterus (n = 2), or
neurological signs (n = 1). Some of the included cats
showed several of these signs. For all cats in the control
group, a disease other than FIP was definitively
diagnosed either at full post-mortem examination plus
histopathology (n = 10), by histopathology of organ
samples obtained post-mortem (n = 1), by bacterial
culture and cytology diagnosing bacterial pleuritis
(n = 2), by echocardiography diagnosing decompensated
cardiac disease explaining pleural or abdominal effusion
(n = 7), or by cytology diagnosing neoplasia (n = 5).
Samples
In total, 59 effusion samples and 17 serum/plasma sam-
ples were collected between 2009 and 2014. Effusion
fluids (34 ascites, 25 pleural effusions) of 43 cats (25
with FIP, 18 controls) were stored at −80 °C and effusion
fluids of 16 cats (ten with FIP, six controls) were stored
at −20 °C. Of twelve of the cats (nine with FIP, three
controls) for which blood was available, plasma was ob-
tained and stored at −80 °C in 2 mL low temperature
freezer vials (VWR International GmbH) until assayed.
Of the remaining five cats (all of them had FIP) for
which blood was available, serum was obtained and
stored at −20 °C in 1.5 mL Eppendorf Safe-Lock micro-
centrifuge tubes (Eppendorf GmbH) until assayed.
All samples collected ante-mortem were originally ob-
tained for diagnostic and, in the case of effusion, also for
therapeutic purposes.
Real-time RT-PCR
Real-time RT-PCR was performed blinded with regard
to the final diagnosis.
Total nucleic acid was extracted from effusion and
serum/plasma samples by QIAamp DNA Blood BioRobot
MDx Kit on an automated Qiagen platform (QIAGEN
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GmbH, Hilden, Germany) according to the manufac-
turer instructions with slight modifications. In order
to first detect FCoV and second to pathotype the
FCoV strain, three real-time PCR assays were
performed in parallel as singleplex reactions at a
commercial reference laboratory (IDEXX Laboratories,
Ludwigsburg, Germany): the first real-time PCR was
based on the 7b gene [26] to quantify viral load, the
other two real-time PCRs were targeting the M1058L
and S1060A single nucleotide polymorphisms de-
scribed before to correlate with the occurrence of the
lethal FIPV genotype [15]. These two PCR tests allow
typing of an FCoV strain based on the presence
(FIPV) or absence (FECV) of one of two single
nucleotide polymorphisms within the fusion peptide
of the spike gene. Briefly, highly specific hydrolysis
probes were designed to either detect the mutation at
position 3174 or 3180 (corresponding to amino acid
positions 1058 and 1060, M1058L and S1060A of ref-
erence sequence FJ938051 [15], respectively) or wild-
type sequences by using an allelic discrimination
approach using real-time PCR. Fluorescence inten-
sities were used to calculate ratios of the probes
detecting the mutation or the wildtype sequences.
FIPV was assigned if the mutation probe exceeded a
2-fold higher fluorescence than the wildtype probe.
Real-time PCR was run with six quality controls
(Table 3).
Interpretation of real-time RT-PCR results
According to the outcome of the typing assay, there
were six possible results of the real-time RT-PCR.
1. Pathotype FIPV: The mutated pathotype (containing
either M1058L or S1060A) was detected in the
sample.
2. Pathotype FECV: Feline enteric coronavirus without
spike gene mutations was detected in the sample.
3. Mixed pathotype: A mixed population of FECV
and FIPV was detected in the sample.
4. Below limit of detection (BLD): FCoV RNA viral
load was low (below 1.5 million viral RNA
equivalents per mL of sample). Owing to the
insufficient number of viral RNA targets,
pathotyping was not possible.
5. Indeterminate (IND): FCoV RNA viral load was high
(above 1.5 million viral RNA equivalents per mL of
sample), but pathotyping was not possible due to
the occurrence of an unknown FCoV strain (failed
amplification) or infection with a serotype II FCoV
strain.
6. Negative: No FCoV RNA was detected in the
sample.
Statistical evaluation
Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and overall accuracy
Fig. 1 Morphological and immunohistochemical diagnosis of feline infectious peritonitis (FIP) featuring typical effusion cytology (a), subcapsular
changes in visceral organs (b; liver), inflammatory and fibrinonecrotic changes (c) and macrophages immunopositive for feline coronavirus (FCoV)
antigen (d). Staining: a,c: haematoxylin-eosin; d: haematoxylin. Scale bar: 75 μm for a and c; 1 cm for b, 25 μm for d
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(sum of true positive and true negative test results di-
vided by the total number of test results) were calculated
using a four-field-chart. To quantify uncertainty, 95%
confidence intervals (95% CI) were calculated. A sample
containing a mixed pathotype was defined as a positive
result. Samples typed as BLD or IND were defined as a
negative result, as no pathotype could be determined.
Results
The FIPV pathotype was detected in 25/59 effusion
samples. Of these, 24 were from cats with FIP, but
one effusion sample from a control cat was also posi-
tive for FIPV with mutation M1058L. Mutation
M1058L was found in 23/25 FIPV samples. Mutation
S1060A was found in none of the FIPV samples. A
mixed pathotype of FIPV and FECV was detected in
2/59 effusion samples (all from cats with FIP). In 12/
59 effusion samples, FCoV RNA was detected, but
pathotyping was not possible (BLD or IND). The
remaining 22/59 effusion samples did not contain
FCoV RNA (Tables 1, 2, 4, and 5).
Real-time RT-PCR was negative in 15/17 serum/
plasma samples. In the remaining two serum/plasma
samples (all from cats with FIP), FCoV RNA could be
detected, but only in low concentrations (BLD). There-
fore, the pathotype could not be determined. None of
the serum/plasma samples of control cats contained
FCoV RNA (Tables 1, 2, 6, and 7).
Sensitivity, specificity, PPV, NPV, and overall accuracy
are shown in Table 8.
Discussion
This study evaluated the use of a new diagnostic test
which is able to distinguish FIPV from FECV pathotypes
in the diagnosis of FIP based on the presence of muta-
tion M1058L or S1060A in the FCoV spike protein.
In a lethal disease like FIP, specificity of a diagnostic
test is more important than sensitivity, because it helps
to prevent euthanasia of cats misdiagnosed with FIP.
Specificity of the real-time RT-PCR in effusion was
95.8%. The FIPV pathotype (M1058L) was found in an
effusion sample from one control cat that had chronic
kidney disease. There are several reasons that could
explain this positive result. First, FCoV spike protein
mutations M1058L and S1060A have previously been
discussed as being a marker for the systemic spread of
the virus rather than for the FIP phenotype, since they
could also be found in tissue samples of healthy cats in-
fected with FCoV [14]. If this was correct, then it would
be possible that the cat was infected with a “benign”
FCoV that spread systemically and therefore exhibited
mutation M1058L. Second, full post-mortem examin-
ation including histopathology was performed in the cat
and did not reveal any typical changes indicative of FIP.
Nevertheless, it cannot be excluded that the cat suffered
from early-stage FIP in addition to chronic kidney
disease, but histopathological changes of FIP were still
absent. Finally, it is possible that the result was a true
false positive due to a methodological error.
The effusion samples of two control cats contained
FCoV RNA but the pathotype could not be determined
due to a low virus load (BLD). If a PCR had been used
Table 3 Details of the six quality controls used in the real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay
quality controls goal of quality controls
1 PCR positive controls (quantitatively¸ using synthetic DNA covering the real-time
PCR target region (Integrated DNA Technologies IDT, Coralville, IA, USA))
functionality of PCR test protocols
2 PCR negative controls (PCR-grade nuclease free water) absence of contamination in reagents
3 negative extraction controls (extraction positions filled with lysis solution and
PCR-grade nuclease free water only)
absence of cross-contamination during the extraction process
4 RNA pre-analytical quality control targeting feline ssr rRNA (18S rRNA) gene
complex
quality and integrity of the RNA as a measure of sample quality
5 a swab-based environmental contamination monitoring control absence of contamination in laboratory
6 spike-in internal positive control (using lambda phage DNA) absence of PCR inhibitory substances as a carryover from
sample matrix
Table 4 Results of effusion samples (n = 59)
group FIPVa M1058L FIPVa S1060A FECVb mixed pathotypea BLDb INDb negativeb total
FIP 22 0 0 2 7 3 1 35
controls 1 0 0 0 2 0 21 24
total 23 0 0 2 9 3 22 59
BLD feline coronavirus present, but below limit of detection, FECV feline enteric coronavirus, FIP feline infectious peritonitis, FIPV feline infectious peritonitis virus,
IND feline coronavirus present, but indeterminate sequence variations
aDefined as positive for statistical analysis
bDefined as negative for statistical analysis
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that was not able to differentiate pathotypes, these cats
would have falsely been diagnosed as having FIP. This
fact emphasizes that the detection of any FCoV in
effusion is not accurate enough to establish the diagnosis
FIP. It has been shown previously that FECV can
circulate systemically in blood monocytes during initial
infection [12].
A moderate sensitivity of 68.6% was found in effusion
in the present study. This is comparable to or even lower
than sensitivities reported in recent studies (65–89%) for
different RT-PCR assays of effusions [22, 23, 27]. Most of
these earlier studies determined the sensitivity of a
RT-PCR that did not distinguish the two FCoV pathotypes
[22, 23]. In contrast, the present study was designed to
allow pathotyping of FCoV. In order to prevent false posi-
tive real-time RT-PCR results arising from the detection
of rare random spike gene mutations, the degree of
fluorescence for the reported pathotype needed to exceed
twice that of the other pathotype. Therefore, even FCoV-
positive samples were regarded as negative for the calcula-
tion of sensitivity if they did not allow definitive determin-
ation of either FIPV or FECV. Three of the effusion
samples from cats with FIP typed as IND (high viral load
but pathotyping was not possible) and therefore were con-
sidered negative for the calculation of sensitivity despite a
high viral load. Additionally, in two of the serum/plasma
and seven of the effusion samples from cats with FIP,
FCoV RNA was detected, but the concentration was too
low to allow pathotyping and therefore, these samples also
were considered negative for the calculation of sensitivity.
If sensitivity of the real-time RT-PCR had only been calcu-
lated for the detection of FCoV in general in the study
population, then sensitivity would have been much better
(97.1% for effusion and 14.3% for serum/plasma).
The FIPV pathotype was detected in the majority (24/34,
71%) of FCoV-positive effusion samples from cats with FIP.
Substitution M1058L was found in 22/34 (65%), substitu-
tion S1060A in 0/34. These results are quite similar to a re-
cent study detecting M1058L in 65% and S1060A in 6% of
FCoV-positive effusions from cats with FIP [23]. Two of
the effusion samples of cats with FIP were typed as mixed
pathotype, meaning that populations of FECV and FIPV
were present in the cat at the same time. It is likely that
these cats were in an early stage during the transition of
FECV to FIPV. Additionally, it is conceivable that these cats
with FIP were superinfected with an FECV, as described
previously [28, 29], and that their effusion samples were
tested positive for both pathotypes due to leakage of FECV
into the effusion.
As stated before, three of the effusion samples of cats
with FIP typed as IND (high virus load but pathotyping
was not possible). The reason for this might be the exist-
ence of unknown spike gene sequence variations in the
sample, which are not recognized by the current primer
set. Since the spike gene assay is specific for serotype I
FCoV, infection with a serotype II FCoV also could cause
typing as IND. Cats with FIP have been shown to exhibit
higher viral loads than healthy FECV-infected cats [30]
and therefore, if a sample is typed as IND, it is likely that
the cat has FIP. Possibly, these cats exhibited alternative
mutations in other parts of their genome that are character-
istic for the development of the FIPV genotype. The 3c gene
and other regions in the S1 and S2 domains of the spike
gene have been identified as other potential sites for muta-
tion(s) involved in FIP pathogenesis [16, 28, 29, 31, 32]. For
example, variations in a furin cleavage site in the region
between receptor-binding (S1) and fusion (S2) domains of
the spike gene were detected when comparing FECV and
FIPV sequences [16]. Another study compared FCoV from
FIP lesions with FCoV from the feces of healthy cats and
identified a consistent substitution of isoleucine with threo-
nine at position 1108 of the spike protein in cats with FIP
[32]. Additionally, mutations of the 3c gene might contrib-
ute to FIP pathogenesis. Mutations in this gene were
observed in the majority of FIPV, whereas an intact 3c gene
Table 5 Results of effusion samplesa
FIP control total
positive 24 1 25
negative 11 23 34
total 35 24 59
FIP feline infectious peritonitis
aBLD (feline coronavirus present, but below limit of detection) and IND (feline
coronavirus present, but indeterminate sequence variations) were defined as
negative for statistical analysis, as the pathotype could not be determined. A
mixed pathotype of feline infectious peritonitis virus and feline enteric
coronavirus was defined as positive, as the mutated pathotype was detected
Table 6 Results of serum/plasma samples (n = 17)
group FIPVa M1058L FIPVa S1060A FECVb mixed pathotypea BLDb INDb negativeb total
FIP 0 0 0 0 2 0 12 14
controls 0 0 0 0 0 0 3 3
total 0 0 0 0 2 0 15 17
BLD feline coronavirus present, but below limit of detection, FECV feline enteric coronavirus, FIP feline infectious peritonitis, FIPV feline infectious peritonitis virus,
IND feline coronavirus present, but indeterminate sequence variations
aDefined as positive for statistical analysis
bDefined as negative for statistical analysis
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was detected in most FECV, suggesting that the 3c gene
also plays a role in the pathogenesis of FIP [28, 29, 32, 33].
It should be considered to retest cats with effusion samples
typed as BLD or IND in order to increase the possibility of
correctly identifying the FIPV or FECV pathotype. Add-
itionally, an effusion sample typed as IND should at least
raise a strong suspicion of FIP, especially if other clinical or
laboratory parameters are indicative of FIP.
Sensitivity in serum/plasma was low, confirming re-
cent studies [22, 34]. A low concentration of FCoV RNA
was detected in the serum/plasma of two cats with FIP,
but the low virus load did not allow pathotype determin-
ation. Thus, sensitivity of the real-time RT-PCR in
serum/plasma was 0%. This is in contrast to results of
previous studies evaluating different RT-PCR assays and
reporting sensitivities of 53–87% using serum, plasma,
or whole blood [24, 25, 35, 36]. Nevertheless, in regard
of the findings of a recent study, a low sensitivity in
blood was expected, as FCoV RNA could not be de-
tected in the whole blood, plasma, or white cell fraction
of cats with experimentally induced FIP at any stage of
disease. In the cats with FIP, viremia was either non-
existent, or virus load was below the detection limit
[34]. It is also likely that in the present study the major-
ity of cats with FIP either were not viremic or that FCoV
RNA levels were below detection limit of the real-time
RT-PCR. It could be argued that sensitivity would have
been better when investigating whole blood, as FIPV
replication is restricted to macrophages [34, 37, 38].
However, real-time RT-PCR of serum and peripheral
blood mononuclear cells (PBMC) has been compared
and both showed rather low sensitivities, even though
the sensitivity of PBMC (31.6%) was slightly better than
that of serum (23.1%) [22]. In general, viral load in
effusion is much higher than in blood [34].
One limitation of the present study was the inclusion
criterion for some of the control cats. Histopathology
could not be performed in all cats and confirmation of
diagnosis was therefore achieved ante-mortem in 14 of
the 25 control cats. Consequently, it cannot be totally
excluded that some of these cats suffered from FIP in
addition to their diagnosed diseases. Nevertheless, this
seems rather unlikely, as real-time RT-PCR was false
positive only in one of the control cats and in this spe-
cific cat, histopathology had been performed. A second
limitation of the present study is the fact that in some of
the cats, only one sample type (effusion or serum/
plasma) was available and overall, the number of avail-
able serum/plasma samples was rather low.
Conclusions
This study evaluated a discriminating real-time RT-PCR
using effusion and/or serum/plasma in the diagnosis of
FIP. The results indicate that the detection of the FIPV
pathotype with substitution M1058L is very specific for
the FIP phenotype and can be a useful tool in the diag-
nosis of FIP. Nevertheless, substitution M1058L was also
detected in one control cat without FIP. As none of the
FIPV-positive effusion samples contained substitution
S1060A, it is considered a weak discriminatory factor for
the diagnosis of FIP. The fact that in two other control
cats FCoV was detected, even though the pathotype
could not be determined, shows that FCoV can cause
viremia and therefore, traditional non-discriminating
RT-PCR is not sufficient to definitively diagnose FIP.
Discriminative RT-PCR should be performed in order to
minimize the risk of euthanasia of cats suffering from
different diseases. The use of serum/plasma is not rec-
ommended owing to the low viral load in blood.
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